× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
   

more details ...

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Interactive explorer of NMA results

5CODEX (Tomazini), 2020 CAPE-COVID, 2020 Steroids-SARI, 2020 DEXA-COVID19, 2020 Jamaati, 20211CAP-China (Wang et al.), 202011Li, 2020 Rasheed, 2020 O’Donnell, 2021 Pouladzadeh, 2021 PlasmAr, 2020 AlQahtani, 2020 CAPSID, 2021 REMAP-CAP (plasma), 2021 Sekine (PLACOVID), 2021 RECOVER, 2021 CP-COVID-19, 20211COV-BARRIER (critically ill), 20224Rahmani, 2020 Darazam (COVIFERON Interferon beta-1a), 2021 Darazam (COVIFERON Interferon beta-1b), 2021 Kalil (ACTT-3), 20217CORIMUNO-TOCI-1 (Group 1), 2020 REMAP-CAP (tocilizumab), 2021 Veiga, 2021 COVACTA (Rosas), 2020 Talaschian, 2021 CORIMUNO-TOCI-ICU (Group 2), 2020 Rosas (REMDACTA), 20212Lescure (Sarilumab 400mg), 2021 Lescure (Sarilumab 200mg), 2021baricitinib vs. control 0.54 [0.28; 1.03]0.54 [0.28;1.03]baricitinib vs. control 0.54 [0.28; 1.03]baricitinib vs. convalescent plasma treatment 0.60 [0.30; 1.19]0.60 [0.30;1.19]baricitinib vs. convalescent plasma treatment 0.60 [0.30; 1.19]baricitinib vs. corticosteroids 0.61 [0.29; 1.27]0.61 [0.29;1.27]baricitinib vs. corticosteroids 0.61 [0.29; 1.27]baricitinib vs. interferon 0.89 [0.34; 2.32]0.89 [0.34;2.32]baricitinib vs. interferon 0.89 [0.34; 2.32]baricitinib vs. remdesivir 0.49 [0.17; 1.44]0.49 [0.17;1.44]baricitinib vs. remdesivir 0.49 [0.17; 1.44]baricitinib vs. sarilumab 0.49 [0.19; 1.28]0.49 [0.19;1.28]baricitinib vs. sarilumab 0.49 [0.19; 1.28]baricitinib vs. tocilizumab 0.58 [0.29; 1.16]0.58 [0.29;1.16]baricitinib vs. tocilizumab 0.58 [0.29; 1.16]control vs. baricitinib 1.85 [0.97; 3.53]1.85 [0.97;3.53]control vs. baricitinib 1.85 [0.97; 3.53]control vs. convalescent plasma treatment 1.11 [0.86; 1.42]1.11 [0.86;1.42]control vs. convalescent plasma treatment 1.11 [0.86; 1.42]control vs. corticosteroids 1.13 [0.80; 1.60]1.13 [0.80;1.60]control vs. corticosteroids 1.13 [0.80; 1.60]control vs. interferon 1.65 [0.82; 3.35]1.65 [0.82;3.35]control vs. interferon 1.65 [0.82; 3.35]control vs. remdesivir 0.91 [0.38; 2.15]0.91 [0.38;2.15]control vs. remdesivir 0.91 [0.38; 2.15]control vs. sarilumab 0.91 [0.45; 1.84]0.91 [0.45;1.84]control vs. sarilumab 0.91 [0.45; 1.84]control vs. tocilizumab 1.08 [0.83; 1.39]1.08 [0.83;1.39]control vs. tocilizumab 1.08 [0.83; 1.39]convalescent plasma treatment vs. baricitinib 1.67 [0.84; 3.34]1.67 [0.84;3.34]convalescent plasma treatment vs. baricitinib 1.67 [0.84; 3.34]convalescent plasma treatment vs. control 0.90 [0.70; 1.16]0.90 [0.70;1.16]convalescent plasma treatment vs. control 0.90 [0.70; 1.16]convalescent plasma treatment vs. corticosteroids 1.02 [0.67; 1.57]1.02 [0.67;1.57]convalescent plasma treatment vs. corticosteroids 1.02 [0.67; 1.57]convalescent plasma treatment vs. interferon 1.49 [0.71; 3.16]1.49 [0.71;3.16]convalescent plasma treatment vs. interferon 1.49 [0.71; 3.16]convalescent plasma treatment vs. remdesivir 0.82 [0.34; 2.01]0.82 [0.34;2.01]convalescent plasma treatment vs. remdesivir 0.82 [0.34; 2.01]convalescent plasma treatment vs. sarilumab 0.83 [0.39; 1.74]0.83 [0.39;1.74]convalescent plasma treatment vs. sarilumab 0.83 [0.39; 1.74]convalescent plasma treatment vs. tocilizumab 0.97 [0.68; 1.39]0.97 [0.68;1.39]convalescent plasma treatment vs. tocilizumab 0.97 [0.68; 1.39]corticosteroids vs. baricitinib 1.64 [0.79; 3.41]1.64 [0.79;3.41]corticosteroids vs. baricitinib 1.64 [0.79; 3.41]corticosteroids vs. control 0.88 [0.62; 1.25]0.88 [0.62;1.25]corticosteroids vs. control 0.88 [0.62; 1.25]corticosteroids vs. convalescent plasma treatment 0.98 [0.64; 1.50]0.98 [0.64;1.50]corticosteroids vs. convalescent plasma treatment 0.98 [0.64; 1.50]corticosteroids vs. interferon 1.46 [0.67; 3.21]1.46 [0.67;3.21]corticosteroids vs. interferon 1.46 [0.67; 3.21]corticosteroids vs. remdesivir 0.80 [0.32; 2.03]0.80 [0.32;2.03]corticosteroids vs. remdesivir 0.80 [0.32; 2.03]corticosteroids vs. sarilumab 0.81 [0.37; 1.77]0.81 [0.37;1.77]corticosteroids vs. sarilumab 0.81 [0.37; 1.77]corticosteroids vs. tocilizumab 0.95 [0.62; 1.46]0.95 [0.62;1.46]corticosteroids vs. tocilizumab 0.95 [0.62; 1.46]interferon vs. baricitinib 1.12 [0.43; 2.91]1.12 [0.43;2.91]interferon vs. baricitinib 1.12 [0.43; 2.91]interferon vs. control 0.60 [0.30; 1.22]0.60 [0.30;1.22]interferon vs. control 0.60 [0.30; 1.22]interferon vs. convalescent plasma treatment 0.67 [0.32; 1.41]0.67 [0.32;1.41]interferon vs. convalescent plasma treatment 0.67 [0.32; 1.41]interferon vs. corticosteroids 0.68 [0.31; 1.50]0.68 [0.31;1.50]interferon vs. corticosteroids 0.68 [0.31; 1.50]interferon vs. remdesivir 0.55 [0.18; 1.67]0.55 [0.18;1.67]interferon vs. remdesivir 0.55 [0.18; 1.67]interferon vs. sarilumab 0.55 [0.20; 1.49]0.55 [0.20;1.49]interferon vs. sarilumab 0.55 [0.20; 1.49]interferon vs. tocilizumab 0.65 [0.31; 1.38]0.65 [0.31;1.38]interferon vs. tocilizumab 0.65 [0.31; 1.38]remdesivir vs. baricitinib 2.04 [0.69; 5.97]2.04 [0.69;5.97]remdesivir vs. baricitinib 2.04 [0.69; 5.97]remdesivir vs. control 1.10 [0.47; 2.60]1.10 [0.47;2.60]remdesivir vs. control 1.10 [0.47; 2.60]remdesivir vs. convalescent plasma treatment 1.22 [0.50; 2.98]1.22 [0.50;2.98]remdesivir vs. convalescent plasma treatment 1.22 [0.50; 2.98]remdesivir vs. corticosteroids 1.24 [0.49; 3.15]1.24 [0.49;3.15]remdesivir vs. corticosteroids 1.24 [0.49; 3.15]remdesivir vs. interferon 1.82 [0.60; 5.54]1.82 [0.60;5.54]remdesivir vs. interferon 1.82 [0.60; 5.54]remdesivir vs. sarilumab 1.01 [0.33; 3.05]1.01 [0.33;3.05]remdesivir vs. sarilumab 1.01 [0.33; 3.05]remdesivir vs. tocilizumab 1.18 [0.48; 2.90]1.18 [0.48;2.90]remdesivir vs. tocilizumab 1.18 [0.48; 2.90]sarilumab vs. baricitinib 2.03 [0.78; 5.25]2.03 [0.78;5.25]sarilumab vs. baricitinib 2.03 [0.78; 5.25]sarilumab vs. control 1.09 [0.54; 2.20]1.09 [0.54;2.20]sarilumab vs. control 1.09 [0.54; 2.20]sarilumab vs. convalescent plasma treatment 1.21 [0.58; 2.55]1.21 [0.58;2.55]sarilumab vs. convalescent plasma treatment 1.21 [0.58; 2.55]sarilumab vs. corticosteroids 1.24 [0.57; 2.70]1.24 [0.57;2.70]sarilumab vs. corticosteroids 1.24 [0.57; 2.70]sarilumab vs. interferon 1.81 [0.67; 4.89]1.81 [0.67;4.89]sarilumab vs. interferon 1.81 [0.67; 4.89]sarilumab vs. remdesivir 0.99 [0.33; 3.01]0.99 [0.33;3.01]sarilumab vs. remdesivir 0.99 [0.33; 3.01]sarilumab vs. tocilizumab 1.18 [0.56; 2.48]1.18 [0.56;2.48]sarilumab vs. tocilizumab 1.18 [0.56; 2.48]tocilizumab vs. baricitinib 1.72 [0.86; 3.44]1.72 [0.86;3.44]tocilizumab vs. baricitinib 1.72 [0.86; 3.44]tocilizumab vs. control 0.93 [0.72; 1.20]0.93 [0.72;1.20]tocilizumab vs. control 0.93 [0.72; 1.20]tocilizumab vs. convalescent plasma treatment 1.03 [0.72; 1.47]1.03 [0.72;1.47]tocilizumab vs. convalescent plasma treatment 1.03 [0.72; 1.47]tocilizumab vs. corticosteroids 1.05 [0.68; 1.62]1.05 [0.68;1.62]tocilizumab vs. corticosteroids 1.05 [0.68; 1.62]tocilizumab vs. interferon 1.54 [0.73; 3.26]1.54 [0.73;3.26]tocilizumab vs. interferon 1.54 [0.73; 3.26]tocilizumab vs. remdesivir 0.84 [0.34; 2.07]0.84 [0.34;2.07]tocilizumab vs. remdesivir 0.84 [0.34; 2.07]tocilizumab vs. sarilumab 0.85 [0.40; 1.79]0.85 [0.40;1.79]tocilizumab vs. sarilumab 0.85 [0.40; 1.79]Risk of bias: - high: 0.0 % - some concerns: 60.0 % - low: 40.0 % - NA: 0.0 %corticosteroidsRisk of bias: - high: 0.0 % - some concerns: 0.0 % - low: 100.0 % - NA: 0.0 %remdesivirRisk of bias: - high: 0.0 % - some concerns: 63.6 % - low: 36.4 % - NA: 0.0 %convalescent plasma treatmentRisk of bias: - high: 0.0 % - some concerns: 0.0 % - low: 100.0 % - NA: 0.0 %baricitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtofacitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcasirivimab/imdevimab (Ronapreve)Risk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %interferonRisk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %tocilizumab Risk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %sarilumabRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcontroldirect evidencenetwork meta-analysis ROB:highsome concernslowNA

Click on treatment name to display related network evidence

T vs. C corticosteroidsremdesivirconvalescent plasma treatmentbaricitinibtofacitinibcasirivimab/imdevimab (Ronapreve)interferontocilizumab sarilumabcontrol
corticosteroids---0.80
0.32; 2.03		0.98
0.64; 1.50		1.64
0.79; 3.41		NANA1.46
0.67; 3.21		0.95
0.62; 1.46		0.81
0.37; 1.77		0.88
0.62; 1.25
remdesivir1.24
0.49; 3.15		---1.22
0.50; 2.98		2.04
0.69; 5.97		NANA1.82
0.60; 5.54		1.18
0.48; 2.90		1.01
0.33; 3.05		1.10
0.47; 2.60
convalescent plasma treatment1.02
0.67; 1.57		0.82
0.34; 2.01		---1.67
0.84; 3.34		NANA1.49
0.71; 3.16		0.97
0.68; 1.39		0.83
0.39; 1.74		0.90
0.70; 1.16
baricitinib0.61
0.29; 1.27		0.49
0.17; 1.44		0.60
0.30; 1.19		---NANA0.89
0.34; 2.32		0.58
0.29; 1.16		0.49
0.19; 1.28		0.54
0.28; 1.03
tofacitinibNANANANA---NANANANANA
casirivimab/imdevimab (Ronapreve)NANANANANA---NANANANA
interferon0.68
0.31; 1.50		0.55
0.18; 1.67		0.67
0.32; 1.41		1.12
0.43; 2.91		NANA---0.65
0.31; 1.38		0.55
0.20; 1.49		0.60
0.30; 1.22
tocilizumab 1.05
0.68; 1.62		0.84
0.34; 2.07		1.03
0.72; 1.47		1.72
0.86; 3.44		NANA1.54
0.73; 3.26		---0.85
0.40; 1.79		0.93
0.72; 1.20
sarilumab1.24
0.57; 2.70		0.99
0.33; 3.01		1.21
0.58; 2.55		2.03
0.78; 5.25		NANA1.81
0.67; 4.89		1.18
0.56; 2.48		---1.09
0.54; 2.20
control1.13
0.80; 1.60		0.91
0.38; 2.15		1.11
0.86; 1.42		1.85
0.97; 3.53		NANA1.65
0.82; 3.35		1.08
0.83; 1.39		0.91
0.45; 1.84		---

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons